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The antiphospholipid syndrome (APS) is a common cause of both arterial and venous thrombosis. While studies exist
demonstrating the role of APS in coronary artery bypass graft failure, its role in stent thrombosis is less clearly documented.
Also, a literature search of PubMed did not reveal any articles regarding the coexistence of clopidogrel resistance and APS
despite increasing awareness of resistance to clopidogrel treatment. We present a case of a 59-year-old male having recurrent
myocardial infarction after subacute restenosis of multiple drug-eluting stents despite anticoagulant therapy. The patient had in-
stent thrombosis of seven drug-eluting stents in a course of eight days. He was subsequently found to have mild elevation of
IgG anticardiolipin (aCL) antibody titers and resistance to clopidogrel. Long-term anticoagulation with a combination of low-
molecular-weight heparin, clopidogrel, and aspirin has been eﬀective. While the patient’s aCL titer level was not elevated above the
level required by the current diagnostic criteria for APS, we believe that this patient suﬀers from the antiphospholipid syndrome.
We will discuss some of the controversies surrounding the diagnosis of APS as well as appropriate treatment and recognition of
the coexistence of APS and clopidogrel resistance in patients with stent thrombosis.
1.Introduction
The antiphospholipid syndrome (APS) is an increasingly
recognized cause of thrombotic events in patients. Antiphos-
pholipid syndrome is the most common acquired cause
of venous and/or arterial thrombosis and is most often
associated with coronary, cerebrovascular, retinal artery,
placental, and deep vein thrombosis [1]. There is evidence
that anticardiolipin antibody titers have a direct correlation
with the incidence of coronary artery bypass graft occlusion
[2]; however, there are few reports of acute stent thrombosis
in the literature [3–5].
Acute drug-eluting stent thrombosis has also been asso-
ciated with clopidogrel resistance [6]. Studies have shown
signiﬁcant increases in major adverse cardiac events after
coronary intervention in patients treated with clopidogrel
who have decreased platelet aggregation [7]. The impli-
cations of this phenomenon on patients with coexisting
hypercoagulable disorders are potentially life-threatening
and should be recognized early.
We present a case of multiple acute stent thromboses
associated with clopidogrel resistance and elevations in
anticardiolipinantibodylevels,whichareinsuﬃcienttomeet
the diagnostic criteria of APS. These patients may be part
of the clinical continuum of “seronegative” APS patients
[8] and those who meet the laboratory criteria. We hope
to illustrate potential weaknesses of the current diagnostic
criteria and the importance of recognizing clopidogrel
resistance in hypercoagulable patients to increase detection
of at-risk patients.
2. Case Presentation
A 59-year-old male presented to the emergency room with
sudden, sharp, left-sided chest pain without radiation. He2 Case Reports in Medicine
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Figure 1: Left circumﬂex artery before (a) and after (b) stent placement during the patient’s third cardiac catheterization.
has a long-standing history of hypertension, hyperlipidemia,
and coronary artery disease. He had a previous myocardial
infarction approximately 10 years prior for which he had
a bare-metal stent placed in his right coronary artery. The
patient has a 50-pack-year history of smoking, but he quit
10 years ago after his ﬁrst myocardial infarction. He does
not drink alcohol or use illicit drugs. His family history is
only positive for hypertension. He was compliant with his
medications which were lisinopril, amlodipine, simvastatin,
metoprolol, omeprazole, and a 325mg aspirin.
H ew a sf o u n dt oh a v ean o r m a lc o m p l e t eb l o o dc o u n t ,
with a hemoglobin of 13.8g/dL, hematocrit of 40%, white
blood cell count of 6,700/mm3, and platelet count of
266,000/mm3. His coagulation studies revealed a partial
thromboplastin time (PTT) of 27 sec (normal 22.1–37.6sec)
and an initial prothrombin time (PT) of 15.7 sec (normal
11.9–14.9sec) with an INR of 1.22. The results of a
complete electrolyte panel, liver function studies, and lipid
panel were all within normal limits except for an HDL
of 26mg/dL (normal 40–60mg/dL). Cardiac enzymes were
initially normal but continued to increase to a CK-MB Index
of8.6(>4consistentwithmyocardialinfarction),CPKof971
U/L (30–200U/L), and Troponin-I of 17.49ng/mL (normal
<1.5ng/mL).
The patient underwent cardiac catheterization and had
60–75% restenosis of the mid right coronary artery (RCA)
and 75% stenosis of the left circumﬂex artery. There was
placement of a 2.75 × 32mm and a 2.75 × 12mm Taxus
drug-eluting stent (Boston Scientiﬁc Corporation) in the
RCA and a 2.75 × 24mm Taxus drug-eluting stent in the
left circumﬂex. Excellent ﬂow was noted and 0% residual
stenosis remained after the stenting. The patient received
600mg clopidogrel after the procedure.
Approximately 90 minutes later, the patient developed
severe chest pain and ST-segment elevation in the inferior
leads on a 12-lead EKG. He was immediately moved to the
catheterization suite for repeat cardiac catheterization. There
were occlusions of both the RCA and left circumﬂex artery
stents. After thrombectomy, the patient received heparin and
eptiﬁbatide. Another 2.5 × 24mm Taxus drug-eluting stent
was placed in the left circumﬂex in addition to previous
stent. The ST-segment returned to baseline and the patient
was without chest pain. The patient was continued on
clopidogrel, aspirin, and eptiﬁbatide for the following four
days and then discharged home.
The patient returned to the emergency room the same
day as discharge complaining of severe chest pain. He again
had ST-segment elevation and underwent cardiac catheter-
ization. There was 100% restenosis of the left circumﬂex
artery (Figure 1), but good inﬂow of the RCA. Thrombec-
tomy was performed, and a 2.5 × 24mm Taxus stent was
deployed in the left circumﬂex. Hypercoagulable laboratory
studies were drawn and thromboelastograph demonstrated
clopidogrel resistance in the patient, with platelet inhibition
of 4%. Therapy was started with eptiﬁbatide, clopidogrel,
aspirin, warfarin, and a heparin drip. After four days, the
INR was 2.41 and the heparin drip was discontinued.
Soon afterwards, the patient developed recurrent chest pain
(Figure 2) and was taken back to the cardiac catheterization
lab. Both the left circumﬂex artery and RCA stents were re-
stenosed. He was referred to surgery for emergent coronary
bypass graft. The patient was stabilized and discharged home
on low-molecular-weight-heparin, aspirin, and clopidogrel.
A complete timeline of events is shown in Figure 3.
After an extensive hypercoagulable work-up, the patient
tested negative for antinuclear antibody (ANA), IgA/IgM
anticardiolipin antibody, homocysteine, IgG/IgA/IgM β2
glycoprotein, Protein C deﬁciency, Protein S deﬁciency, anti-
thrombin III deﬁciency, Factor V Leiden, and Prothrombin
20210A. A dilute Russell Viper venom time was 35sec
(normal <43sec). The only abnormal laboratory values were
an IgG anticardiolipin antibody of 12 (normal <10) and a
diluteprothrombintime(dPT)of63.60(normal0–56.6sec),
with no lupus anticoagulant detected.
In follow-up with the patient, he has remained on low-
molecular-weight heparin, aspirin, and clopidogrel for 6
weeks. He has had no chest pain or other known thrombosis.
His repeated laboratory studies show an undetectable level of
IgG anticardiolipin antibody as well as undetectable levels of
IgA/IgM anticardiolipin antibody or lupus anticoagulant.Case Reports in Medicine 3
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Figure 2: EKG, showing ST-segment elevation in contiguous inferior leads (II, III, aVF), taken after discontinuation of heparin drip and
before undergoing coronary artery bypass grafting.
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Figure 3: Timeline of events, interventions, and medications.
3. Discussion
Clopidogrel resistance is an emerging topic in the litera-
ture. It is unclear whether the phenomenon is merely a
preexisting variability in platelet response to ADP or a true
decrease in response to clopidogrel [9]. Regardless of the
pathophysiology, studies have shown a signiﬁcant increase in
major adverse cardiac events after coronary intervention in
patients treated with clopidogrel who have decreased platelet
aggregation [7]. Nonresponsiveness to clopidogrel also has
a strong correlation with drug-eluting stent thrombosis [6].
However, varying deﬁnitions of “nonresponsiveness” have
made it diﬃcult to know the true incidence of the condition
and the direct correlation with clinical outcomes.
There is evidence that increased dosing of clopidogrel
reduces the incidence of platelet nonresponsiveness [10]
and signiﬁcantly increases clinical outcomes [11, 12]. The
Clopidogrel Optimal Loading Dose Usage to Reduce Recur-
rent Events/Optimal Antiplatelet Strategy for Interventions
(CURRENT/OASIS-7) trial did demonstrate a 30% reduc-
tion in stent thrombosis and a 22% reduction in myocardial
infarction in patients treated with high-dose clopidogrel as
compared to the current dosing guidelines. The high-dose
arm of the study consisted of a 600mg loading dose of
clopidogrel followed by 150mg daily for seven days [13]. In
addition,invitrostudieshavealsoshownthattreatmentwith
eptiﬁbatide and 600mg clopidogrel added a greater than or
equal to 2-fold increase in platelet inhibition compared to
600mg or 300mg clopidogrel alone [14]. The implications
this will have on treatment for patients with hypercoagulable
conditions remain to be seen.
IgG anticardiolipin antibodies (IgG aCL) have been
linked to coronary artery thrombosis. Up to 38.3% of
patients with positive titers for IgG aCL have coronary,
carotid, or peripheral arterial thrombosis. The incidence is
more than doubled compared to patients with the classic
lupus anticoagulant [15]. Coronary artery bypass graft
(CABG) occlusion is also directly correlated with aCL titers
[2]; however, PubMed search of the literature reveals few
previous case reports of APL-associated recurrent stent
thrombosis [3–5]. Unfortunately, it is unknown whether
these patients also demonstrated resistance to clopidogrel.
These case reports, combined with the aforementioned
studies, suggest a correlation in antiphospholipid syndrome
and recurrent stent thrombosis.4 Case Reports in Medicine
Similar to previous case reports, our patient has a strong
propensity to reocclude coronary stenting. The current
consensus criteria for the diagnosis of APS due to IgG
anticardiolipin include clinical evidence of thrombosis in
conjunction with an aCL titer persistently elevated >99th
percentile, or >40 GPL or MPL [16]. Given the patient’s
clinicalmanifestations,increasedINR,andelevatedIgGaCL,
which is not suﬃciently elevated to meet the diagnostic
criteria, we believe that the patient should be classiﬁed
as having antiphospholipid syndrome associated with aCL.
The absence of any other abnormal hematological labs is
consistent with this diagnosis. The patient will receive long-
term ﬁxed-dose anticoagulation; therefore, the absence of
abnormal labs during follow-up may be expected because
therapy has been shown to decrease anticardiolipin antibody
levels, in particular aspirin [17].
There is controversy surrounding the diagnostic criteria
for APS [18]. There have been reports of patients presenting
with thrombotic episodes and normal antibody titers who
were found to be positive 2–7 months later [8]. These
“seronegative” patients suggest that current diagnostic cri-
teria are insuﬃcient to diagnose all aﬀected patients. There
also exists controversy surrounding the laboratory tests
themselves. A study from the First French Anticardiolipin
Standardization Workshop demonstrated a variation of
greater than 70% in IgG aCL between laboratories [19].
We believe that this case represents a patient with APS
who is excluded by the current consensus diagnostic criteria.
An expansion of the criteria should be considered to include
patients with lower antibody titers (cutoﬀ less than the
current 40 GPL or MPL) in light of evidence suggesting a
prothrombotic predisposition in these patients. Also, search
of PubMed reveals no literature regarding the coexistence
of prothrombotic conditions and clopidogrel resistance.
However, we believe tat recognition of this coexistence could
have dramatically altered our patient’s clinical course.
Despite the previously mentioned studies regarding
improved outcomes in clopidogrel-resistant patients with
altered drug regimens, we believe this to still be insuﬃcient
treatment for patients with a coexistent hypercoagulable dis-
order. Awareness of the possibility of prothrombotic condi-
tions coexisting with drug resistance in patients undergoing
clopidogrel therapy could have a dramatic reduction in their
morbidityandmortality.Althoughformalstudiesarelacking
at this time, we suggest the use of antiplatelet agents in
combination with unfractionated or low-molecular-weight
heparin to prevent recurrent stent thrombosis in patients
with antiphospholipid syndrome or increased anticardi-
olipin antibody levels based on our experiences.
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